Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C -

- Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, severe adverse events and discontinuations due to adverse events, vs. peginterferon alfa-2a -

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are pleased that Albuferon met its primary endpoint in the ACHIEVE 2/3 trial. These Phase 3 data show that the efficacy of Albuferon was comparable to Pegasys, with half the injections," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We look forward to having the results of ACHIEVE 1, our other Phase 3 trial of Albuferon, in March 2009. If ACHIEVE 1 is successful, we believe Albuferon could become the market-leading interferon for the treatment of chronic hepatitis C, and we expect that global marketing applications will be filed by fall 2009."

David Nelson, M.D., Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , NEW YORK, Dec. 1 ...arch report is available in its catalogue: ,, ...: Market dynamics and the changing healthcare and ...nker.com/p0165658/Emerging-Clinical-Trial-Location...g-healthcare-and-regulatory-environment.html ,...
(Date:12/1/2009)..., , SHANGHAI, Dec. 1 /PRNewswire-Asia...ary of ShangPharma, a leading China-based Contract...s a winner of the 2009 Deloitte,Technology Fast 50...wing high,tech companies in China. The award is a ...revenue growth from 2006 to 2008. , The r...
(Date:12/1/2009)... Enterprise level storage... care providers without breaking the bank. , ...csDrive, LLC. ( www.pacsdrive.com ), a medical i...a new DICOM compatible cloud storage service. The ...ealth care providers to securely archive medical i...
(Date:12/1/2009)..., , SAN DIEGO, Dec. 1 /PRNewswire... Board: AEMD) announced today that it will present...3, 2009 at 2:00 p.m. (PST) at the Luxe Hotel in Lo...es A. Joyce, will present a corporate overview and...progress for its lead product, the Hemopurifier...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2
...today,received information from Danske Bank, that ...ivsforsikring and Danske Fund FCP - through,acquis...hares of a nominal,value of each DKK 1 correspondi...voting rights in Exiqon A/S., About Exiqon, Exiq...scientific,expertise in gene expression with our p...
...ications bear more than a passing resemblance to d...erally to capture all the colors of the spectrum, ...t from across the spectrum moves through optical c...rcuits contain dimensions measured in nanometers. ...andidate in electrical engineering at Lehigh Unive...
...WYE ) has,announced that Bernard Poussot, 56, Wyet...umed the additional position of Chairman of the Bo...t to a previously announced election by the,Compan...a succession plan,that began in April 2006 when Mr...man. In January 2007, he was named President and C...
Other Biology Technology:Using a grating with a grade, engineers trap a rainbow 2Using a grating with a grade, engineers trap a rainbow 3
(Date:12/1/2009)... United States, the other from Canada, put the sat...ck, on remote Ellesmere Island, only 600 miles fro...what these "North Pole wolves" do in the long, dar...he world., "We first encountered 9-year-old Brut... Geological Survey (USGS) wolf researcher who has ...
(Date:12/1/2009)...wire/ -- iQor, a global provider of business proce... 2009 InfoWorld 100 Awards Top 100 IT project of... This was the first submission for iQor. ,, "We...us list of companies," said Vikas Kapoor, presiden...ng the way we do business, allowing us to work fas...
(Date:12/1/2009)...ideo of individual breast tissue cells reveals a n...otein that cycles between two major compartments i...mplete view of the internal signals that cause bre...ancer and are targets of drug development. , Th... factors, travels back and forth between the nucle...
Breaking Biology News(10 mins):North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4The Jones Center for Diabetes 26amp 3B Endocrine Wellness Selects Retasure to Enhance Diabetes Care 54138 1The Jones Center for Diabetes 26amp 3B Endocrine Wellness Selects Retasure to Enhance Diabetes Care 54138 2UT Southwestern physicians bust myths about insulin 54134 1UT Southwestern physicians bust myths about insulin 54134 2Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 1Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 2
...t seems size does matters after all. But for flyin...ty of Chicago researchers. , In the May 15, 2005,...entists described the effects of size and behavior...als were better gliders. , "Despite their lack of ...rial locomotors," said lead scientist and author J...
...ohns Hopkins infectious disease specialists who ha...combat HIV and AIDS worldwide are warning that lim...al therapies currently being distributed in Africa... can least afford to pay for them. , In an article...h online June 28, infectious disease specialist Jo...
...n early type of antibiotic-resistant bacteria that...0s has re-emerged as one of the community-acquired...in The Lancet tomorrow (Saturday 2 April 2005). , ...at caused a pandemic 40-50 years ago could mean th...be more widespread than previously expected, warns...
Other Biology News:Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 4Community MRSA is re-emergence of 1950s pandemic, study suggests 2
Acridine orange, hemizinc salt from Research Organics, Inc.
Auto/Zyme Reagent Set from Biomeda Corporation
DAPI from Research Organics, Inc.
Agarose, high EEO, Molecular Biology Grade from Research Organics, Inc.
Biology Products: